Impact of the signal path PD-1/PD-L1 on Treg cells and tumor cells

Abstract

Abstract:Programmed death1 (PD1) and its ligand PDL1 are the major members of inhibitory costimulatory molecules and express high in a variety of tumor cells and their associated cells surface, while the proportion of regulatory T cells (Tregs) are abnormally elevated in tumor infiltrating T lymphocytes cells. PDL1 combined with PD1 and Treg help tumors evade immune clearance, weaken immune responses and induce immune tolerance. New researches find that PDL1 plays an important role in the development and function maintenance of inducible Treg (iTreg), and PDL1 signal can change initial CD4+ CD25- T cells into iTreg to play a role of immunosuppression. Research on PD1 signaling pathway can provide a new theoretical basis for the inhibition of tumor immune escape in clinical application of immunotherapy and better treatments.

Key words:Neoplasms,T-lymphocytes,Tumor escape,Programmed cell death 1 receptor

SONG Shu-An, PU Da-Xun, JIANG Tao, JING Qiong-You, WANG Jian-Bing. Impact of the signal path PD-1/PD-L1 on Treg cells and tumor cells[J]. Journal of International Oncology, 2014, 41(11): 808-810.

References

［1］ Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD1,anovel member of the immunoglobulin gene superfamily,upon programmed cell death［J］. EMBO J, 1992, 11( 11): 38873895. ［2］ Freeman GJ, long AJ, Iwai Y, et al. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negulation of lymphocyte activation［J］. J Exp Med, 2000, 192(7): 10271034. ［3］李军, 李佳. PDL1信号的研究进展及在移植耐受调节中的作用［J］. 细胞与分子免疫学杂志, 2011, 27(9): 10361038. ［4］ Jayshree RS, Sreenivas A, Tessy M, , et al. Cell intrinsic&extrinsic factors in cervical carcinogenesis ［J］. Indian J Med Res, 2009, 130(3): 286295. ［5］ Folkl A, Bienzle D. Structure and function of programmed death (PD) molecules［J］. Vet Immunol Immunopathol, 2010, 134(12): 3338. ［6］ Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PDL1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma［J］. Clin Cancer Res， 2009, 15(3): 971979. ［7］ Saresella M, Rainone V, AlDaghri NM, et al. PD1/PDL1 pathway in human pathology［J］. Curr Mol Med， 2012, 12(3): 259267. ［8］ Wing K， Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity［J］. Nat Immunol， 2010, 11(1): 713. ［9］ Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation［J］. Immunity， 2009, 30(5): 646655. ［10］ Francisco LM, Salinas VH, Brown K, et al. PDL1 regulates the development, maintenance, and function of induced regulatory T cells［J］. Exp Med， 2009, 206(13): 30153029. ［11］ Belkaid Y. Role of Foxp3positive regulatory T cells during infection［J］. Eur J Immunol, 2008, 38(4): 918921. ［12］ Zhao X, Ye F, Chen L, et al. Human epithelial ovarian carcinoma cellderived cytokines cooperatively induce activated CD4+CD25-CD45RA+naive T cells to express forkhead box protein 3 and exhibit suppressive abilityin vitro［J］. Cancer Sci, 2009, 100(11): 21432151. ［13］ Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7Hl promotes Tcell apoptosts: a potential mechanism of immune evasion［J］. Nat Med, 2002, 8(8):793800. ［14］ Grellier E, Lécolle K, Rogée S, et al. A fibermodified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors［J］. Mol Cancer, 2011, 10: 105119. ［15］ Pittet CL, Newcombe J, Prat A, et al. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD1 ligand expression in multiple sclerosis［J］.J Neuroinflammation, 2011, 8: 155167. ［16］ Crane CA, Panner A, Murry JC, et al. PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer［J］. Oncogene, 2009, 28(2): 306312. ［17］ Karakhanova S, Meisal S, Ring S, et al. ERK/p38 MAPkinases and PI3K are involved in the differential regulation of B7H1 expression in DC subsets［J］. Eur J Immunol, 2010, 40(1):254266. ［18］ Holets LM, Garletii MZ, Kshirsaqar SK, et al. Differentiationinduced posttranscriptional control of B7H1 in human trophoblast cells［J］. Placenta， 2009, 30(1): 4855.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.